Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

INTRODUCTION: Brentuximab vedotin (SGN-35), an anti-cluster of differentiation (CD)-30 antibody conjugated to the anti-tubulin agent monomethyl auristatin E, has demonstrated promising efficacy and tolerability in relapsed and heavily treated Hodgkin lymphoma (HL). In this study, we report the Asian...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qing-Ming, Hong, Jung Yong, Ko, Young Hyeh, Lin, Shek-Ying, Au, Wing-Yan, Choi, Moon Ki, Park, Silvia, Kim, Seok Jin, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196794/
https://www.ncbi.nlm.nih.gov/pubmed/25328405
http://dx.doi.org/10.2147/OTT.S67380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196794/
https://www.ncbi.nlm.nih.gov/pubmed/25328405
http://dx.doi.org/10.2147/OTT.S67380

Ejemplares similares